{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:57:52Z","timestamp":1791212272361,"version":"4.1.0"},"reference-count":114,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>PARPi, in combination with ionizing radiation, has demonstrated the ability to enhance cellular radiosensitivity in different tumors. The rationale is that the exposure to radiation leads to both physical and biochemical damage to DNA, prompting cells to initiate three primary mechanisms for DNA repair. Two double-stranded DNA breaks (DSB) repair pathways: (1) non-homologous end-joining (NHEJ) and (2) homologous recombination (HR); and (3) a single-stranded DNA break (SSB) repair pathway (base excision repair, BER). In this scenario, PARPi can serve as radiosensitizers by leveraging the BER pathway. This mechanism heightens the likelihood of replication forks collapsing, consequently leading to the formation of persistent DSBs. Together, the combination of PARPi and radiotherapy is a potent oncological strategy. This combination has proven its efficacy in different tumors. However, in prostate cancer, there are only preclinical studies to support it and, recently, an ongoing clinical trial. The objective of this paper is to perform a review of the current evidence regarding the use of PARPi and radiotherapy (RT) in PCa and to give future insight on this topic.<\/jats:p>","DOI":"10.3390\/ijms241612978","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:33:11Z","timestamp":1692581591000},"page":"12978","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-4618","authenticated-orcid":false,"given":"In\u00e9s","family":"Rivero Belench\u00f3n","sequence":"first","affiliation":[{"name":"Urology and Nephrology Department, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Biomedical Institute of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Belen","family":"Congregado Ruiz","sequence":"additional","affiliation":[{"name":"Urology and Nephrology Department, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Biomedical Institute of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-0508","authenticated-orcid":false,"given":"Carmen","family":"Saez","sequence":"additional","affiliation":[{"name":"Biomedical Institute of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-0223","authenticated-orcid":false,"given":"Ignacio","family":"Osman Garc\u00eda","sequence":"additional","affiliation":[{"name":"Urology and Nephrology Department, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Biomedical Institute of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4514-4329","authenticated-orcid":false,"given":"Rafael Antonio","family":"Medina L\u00f3pez","sequence":"additional","affiliation":[{"name":"Urology and Nephrology Department, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Biomedical Institute of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP Inhibitors and prostate cancer: To infinity and Beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ctrv.2010.03.003","article-title":"Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers","volume":"36","author":"Powell","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent Olaparib and Radiotherapy in Patients with Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M.R., and Herskind, C. (2022). Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14194874"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.3748\/wjg.v22.i32.7275","article-title":"Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer","volume":"22","author":"Yang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non\u2013Small Cell Lung Cancer","volume":"27","author":"Peulen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mumtaz, S., Nahushkumar Rana, J., Ha Choi, E., and Han, I. (2022). Microwave Radiation and the Brain: Mechanisms, Current Status, and Future Prospects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169288"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clon.2019.08.006","article-title":"Radiation Track Structure: How the Spatial Distribution of Energy Deposition Drives Biological Response","volume":"32","author":"Hill","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lyu, F., Shang, S.-Y., Gao, X.-S., Ma, M.-W., Xie, M., Ren, X.-Y., Liu, M.-Z., Chen, J.-Y., Li, S.-S., and Huang, L. (2023). Uncovering the Secrets of Prostate Cancer\u2019s Radiotherapy Resistance: Advances in Mechanism Research. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061628"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wilkinson, B., Hill, M.A., and Parsons, J.L. (2023). The Cellular Response to Complex DNA Damage Induced by Ionising Radiation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054920"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rpd\/ncl498","article-title":"Energy deposition stochastics and track structure: What about the target?","volume":"122","author":"Goodhead","year":"2006","journal-title":"Radiat. Prot. Dosim."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: Relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","article-title":"Main steps in DNA double-strand break repair: An introduction to homologous recombination and related processes","volume":"127","author":"Ranjha","year":"2018","journal-title":"Chromosoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1074\/jbc.M706734200","article-title":"PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites","volume":"283","author":"Haince","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ccr.2013.03.025","article-title":"Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation","volume":"23","author":"Li","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.celrep.2015.09.040","article-title":"Poly(ADP-ribose) mediates the BRCA2-dependent early DNA damage response","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.1093\/nar\/gkv939","article-title":"The PIN domain of EXO1 recognizes poly(ADP-ribose) in DNA damage response","volume":"43","author":"Zhang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.emboj.7601015","article-title":"Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells","volume":"25","author":"Hochegger","year":"2006","journal-title":"EMBO J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1093\/nar\/gky088","article-title":"Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors","volume":"46","author":"Yang","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","article-title":"Arequirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage","volume":"31","author":"Masutani","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1128\/MCB.23.11.3974-3981.2003","article-title":"Spatial and temporal cellular responses to single-strand breaks in human cells","volume":"23","author":"Okano","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eaav4340","DOI":"10.1126\/sciadv.aav4340","article-title":"Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies","volume":"5","author":"Chen","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1242\/jcs.039115","article-title":"Radiation-induced mitotic catastrophe in PARG-deficient cells","volume":"122","author":"Ame","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/bi00573a008","article-title":"Nuclear protein modification and chromatin substructure. 3. Relationship between poly(adenosine diphosphate) ribosylation and different functional forms of chromatin","volume":"18","author":"Jump","year":"1979","journal-title":"Biochemistry"},{"key":"ref_37","first-page":"19","article-title":"DNA replication and poly(ADP-ribosyl)ation of chromatin","volume":"58","author":"Anachkova","year":"1989","journal-title":"Cytobios"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/nar\/26.8.1891","article-title":"Functional association of poly(ADP-ribose) polymerase with DNA polymerase \u03b1-primase complex: A link between DNA strand break detection and DNA replication","volume":"26","author":"Dantzer","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/nar\/gkl108","article-title":"Inhibition of poly (ADP-ribose) polymerase activates ATMwhich is required for subsequent homologous recombination repair","volume":"34","author":"Bryant","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1038\/sj.onc.1207491","article-title":"Ablation of PARP-1 does not interfere with the repair of DNA doublestrand breaks, but compromises the reactivation of stalled replication forks","volume":"23","author":"Yang","year":"2004","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1083\/jcb.200806068","article-title":"PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA","volume":"183","author":"Sugimura","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nsmb.2501","article-title":"Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition","volume":"20","author":"Berti","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","article-title":"Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","volume":"72","author":"Ying","year":"2012","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","article-title":"PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation","volume":"9","author":"Ronson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/ncomms3993","article-title":"Poly (ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation","volume":"4","author":"Min","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8460","DOI":"10.1038\/sj.onc.1206897","article-title":"PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase","volume":"22","author":"Rosenthal","year":"2003","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_50","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm.2016.58","article-title":"Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers","volume":"17","author":"Schwertman","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specifickilling of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-018-0612-8","article-title":"Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response","volume":"10","author":"Francica","year":"2018","journal-title":"Genome Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rao, A., Moka, N., Hamstra, D.A., and Ryan, C.J. (2022). Co-Inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now?. Cancers, 14.","DOI":"10.3390\/cancers14030801"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Congregado, B., Rivero, I., Osman, I., Saez, C., and Medina L\u00f3pez, R. (2022). PARP inhibitors: A new horizon for patients with prostate cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061416"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"v884","DOI":"10.1093\/annonc\/mdz394.043","article-title":"Pre-specified interim analysis of GALAHAD: A phase 2 study of niraparib in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects","volume":"30","author":"Smith","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): An open-label, phase 2 trial","volume":"22","author":"Mehra","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2022.40.6_suppl.011","article-title":"Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial","volume":"40","author":"Saad","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","article-title":"Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) withmetastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations","volume":"40","author":"Chi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-662-49651-0_1","article-title":"DNA Repair","volume":"Volume 198","author":"Borgmann","year":"2016","journal-title":"Molecular Radio-Oncology: Recent Results in Cancer Research"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dnarep.2007.02.006","article-title":"DNA double-strand break repair: From mechanistic understanding to cancer treatment","volume":"6","author":"Helleday","year":"2007","journal-title":"DNA Repair"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1128\/MCB.23.16.5706-5715.2003","article-title":"Pathways of DNA double-strand break repair during the mammalian cell cycle","volume":"23","author":"Rothkamm","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1101\/sqb.2005.70.002","article-title":"The ATM-dependent DNA damage signaling pathway","volume":"70","author":"Kitagawa","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/em.21944","article-title":"DNA damage foci: Meaning and significance","volume":"56","author":"Rothkamm","year":"2015","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.radonc.2013.06.022","article-title":"Residual \u03b3H2AX;H2AX foci predict local tumour control after radiotherapy","volume":"108","author":"Koch","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.radonc.2015.08.006","article-title":"Residual gammaH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness","volume":"116","author":"Menegakis","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcdb.2017.01.007","article-title":"Poly(ADP-ribose) polymerase activity and inhibition in cancer","volume":"63","author":"Dulaney","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1093\/nar\/gkn347","article-title":"Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks","volume":"36","author":"Mansour","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"69105","DOI":"10.18632\/oncotarget.19079","article-title":"Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: A systematic review of pre-clinical and clinical human studies","volume":"8","author":"Lesueur","year":"2017","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13046-016-0456-2","article-title":"Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic","volume":"35","author":"Cerrato","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"13770","DOI":"10.1073\/pnas.0906920106","article-title":"Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler","volume":"106","author":"Gottschalk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1535-7163.MCT-05-0418","article-title":"Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis","volume":"5","author":"Godon","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-09-0398","article-title":"Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: A contributory factor to chemopotentiation in vivo?","volume":"15","author":"Ali","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1593\/neo.131604","article-title":"Targeted Radiosensitization of ETS Fusion\u2013Positive Prostate Cancer","volume":"15","author":"Han","year":"2013","journal-title":"Neoplasia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.radonc.2015.08.003","article-title":"In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio","volume":"116","author":"Gani","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41598-018-22289-7","article-title":"Loss of PTEN-assisted G2\/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer","volume":"8","author":"Mansour","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-16-0740","article-title":"Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN\/TP53-deficient prostate cancer to radiation","volume":"16","author":"Tangutoori","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2018.03.007","article-title":"BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy","volume":"423","author":"Oing","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/ijc.32018","article-title":"A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer","volume":"144","author":"Beyer","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/07357907.2021.1899200","article-title":"Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1\/TP53 Loss","volume":"39","author":"Fan","year":"2021","journal-title":"Cancer Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_101","unstructured":"Mottet, N., Bellmunt, J., Briers, E., Bolla, M., Bourke, L., Cornford, P., De Santis, M., Henry, A.M., Joniau, S., and Lam, T.B. (2023). EAU\u2013ESTRO\u2013ESUR\u2013SIOG Guidelines on Prostate Cancer, EAU Guidelines Office."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-0716-2891-1_19","article-title":"Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells","volume":"2609","author":"Makhov","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.annonc.2020.08.2083","article-title":"689TiP NRG Oncology\u2019s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)","volume":"31","author":"Zumsteg","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Parker, C.C., James, N.D., Brawley, C.D., Clarke, N.W., Ali, A., Amos, C.L., Attard, G., Chowdhury, S., Cook, A., and Cross, W. (2022). Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003998"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients with Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials","volume":"40","author":"Deek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-07-0561","article-title":"Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia. Implications for Disease Progression and Radiation Response","volume":"67","author":"Milosevic","year":"2007","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Virtanen, V., Paunu, K., Ahlskog, J.K., Varnai, R., Sipeky, C., and Sundvall, M. (2019). PARP Inhibitors in Prostate Cancer\u2014The Preclinical Rationale and Current Clinical Development. Genes, 10.","DOI":"10.3390\/genes10080565"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12978\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:37:41Z","timestamp":1760128661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":114,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241612978"],"URL":"https:\/\/doi.org\/10.3390\/ijms241612978","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]}}}